Business, Healthcare, Science

ENHERTU® demonstrated statistically significant and clinically meaningful improvement in overall survival in patients with HER2 positive metastatic gastric cancer at interim analysis of DESTINY-gastric04 phase 3 trial

Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU Results will be shared with global regulatory authorities   TOKYO &

Business, Healthcare, Media & Communications, News Now!, Opinions & Philosophy

New podcast aims to alleviate the pain of making healthcare decisions for employers and consumers alike                         

NEW YORK — Employers are often overwhelmed by the daunting task of managing healthcare expenditures, and consumers are craving more transparency and clarity when it comes to understanding their policies and benefits. Ray Kober, the founder of Benefixa, a health insurance agency specializing